中生製藥(01177.HK)將為創新藥遞交ASPS適應症上市申請

阿斯達克財經

2024/12/19

中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合鹽酸安羅替尼膠囊，已向中國藥監局(NMPA)藥品審評中心(CDE)就新增晚期腺泡狀軟組織肉瘤(ASPS)適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。ASPS是安羅替尼即將申報上市的第12個適應症、貝莫蘇拜單抗即將申報上市的第5個適應症，有望為ASPS患者帶來新的治療選擇。...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492145201"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492145201\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492145201?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","is_english":false,"pubTime":"2024-12-19 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492145201","market":"hk","top_or_hot":-1,"title":"中生製藥(01177.HK)將為創新藥遞交ASPS適應症上市申請","media":"阿斯達克財經","content":"<div>\n<p>中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合鹽酸安羅替尼膠囊，已向中國藥監局(NMPA)藥品審評中心(CDE)就新增晚期腺泡狀軟組織肉瘤(ASPS)適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。ASPS是安羅替尼即將申報上市的第12個適應症、貝莫蘇拜單抗即將申報上市的第5個適應症，有望為ASPS患者帶來新的治療選擇。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中生製藥(01177.HK)將為創新藥遞交ASPS適應症上市申請</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中生製藥(01177.HK)將為創新藥遞交ASPS適應症上市申請\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2024-12-19 16:39</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合鹽酸安羅替尼膠囊，已向中國藥監局(NMPA)藥品審評中心(CDE)就新增晚期腺泡狀軟組織肉瘤(ASPS)適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。ASPS是安羅替尼即將申報上市的第12個適應症、貝莫蘇拜單抗即將申報上市的第5個適應症，有望為ASPS患者帶來新的治療選擇。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"創新藥","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN","article_id":"2492145201","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492145201","pubTimestamp":1734597540,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"中生製藥公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合鹽酸安羅替尼膠囊，已向中國藥監局藥品審評中心就新增晚期腺泡狀軟組織肉瘤適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。ASPS是安羅替尼即將申報上市的第12個適應症、貝莫蘇拜單抗即將申報上市的第5個適應症，有望為ASPS患者帶來新的治療選擇。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","06978":"永泰生物-B","01177":"中国生物制药","BK1589":"北水核心资产","BK1191":"制药","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","01477":"欧康维视生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Zhongsheng Pharmaceutical (01177. HK) will submit an ASPS indication marketing application for innovative drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"01177":1,"01477":1,"06978":1},"content_text":"中生製藥(01177.HK) 公布，集團自主研發的1類創新藥貝莫蘇拜單抗注射液聯合鹽酸安羅替尼膠囊，已向中國藥監局(NMPA)藥品審評中心(CDE)就新增晚期腺泡狀軟組織肉瘤(ASPS)適應症的上市申請進行溝通，並獲得CDE書面同意提交上市申請。集團將於近期遞交上市申請。ASPS是安羅替尼即將申報上市的第12個適應症、貝莫蘇拜單抗即將申報上市的第5個適應症，有望為ASPS患者帶來新的治療選擇。貝莫蘇拜單抗聯合安羅替尼有望成為中國首個獲批用於ASPS的PD-L1抑制劑與小分子抗血管生成藥物聯合療法。(sl/da)(港股報價延遲最少十五分鐘。沽空資料截至 2024-12-19 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}